


| | | | | | | | | | | | | | | | | | |
|---|--|-----------------|---|-------------|---|--------------|---|--------------|---------------|-----------------|-------|-------------------|--|-------|--|--|--|
| PTO FORM 4/92 | | | | | | | | | | | | | | | | | |
| FORM PTO-1449 | | | | NOV 25 2002 | | ATTY. DOCKET | | 10872/482274 | | SERIAL NO. | | 60/268,439 | | | | | |
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT | | | | | | | | | | APPLICANT | | | | | | | |
| | | | | | | | | | | FILING DATE | | February 13, 2001 | | GROUP | | | |
| | | | | | | | | | | | | | | | | | |
| Exam Init. | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUB CLASS | | | | | |
| BW | | 4 | 6 | 8 | 3 | 1 | 9 | 5 | Jul 28, 1987 | Mullis et al. | 435 | 6 | | | | | |
| | | 4 | 6 | 8 | 3 | 2 | 0 | 2 | Jul 28, 1987 | Mullis | 435 | 91 | | | | | |
| | | 5 | 4 | 5 | 5 | 1 | 7 | 5 | Oct. 3, 1995 | Wittwer, et al. | 435 | 286.1 | | | | | |
| | | 5 | 8 | 3 | 7 | 8 | 3 | 2 | Nov. 17, 1998 | Chee et al. | 536 | 22.1 | | | | | |
| | | 5 | 8 | 0 | 7 | 5 | 2 | 2 | Sep. 15, 1998 | Brown et al. | 422 | 50 | | | | | |
| OTHER ART (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | | | | | | | | | | | | | | | | | |

- A simple introduction to the science of the polymerase chain reaction, PCR: Basics for beginners, Jan. 31, 01.*
- Adaptation Protocol for Sequence-Specific Detection of DNA with Hybridization Probes, Roche Molecular Biochemicals, Technical Note. No. 3/99.*
- Antin, J. et al., Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-vs-host disease in patients with hemtologic malignancies. Blood: 78: 2139, 1991.*
- Baldanti F, et al., Highlevels of Epstein-Barr virus DNA in blood of solid organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J. Clin Microbiol. 38: 613, 2000.*
- Caplin, et al., The most direct way to monitor PCR amplification for quantification and mutation detection, Roche Moelcular Biochemicals, Biochemica - No. 1, 1999.*
- Choice of Suitable Probe Targets, 1 page article.*
- DeSilva, et al., Rapid Genotyping and Quantification on the LightCycler™ with Hybridization Probes, Biochemica, No. 2, (1998).*
- Groen, Pamela, et al., "Development of a Quantitative EBV PCR Assay for the LightCycler System," 14 pgs, (2001).*
- Henry T., et al., Correlation of Epstein-Barr viral load with development of PTLN in solid organ transplant recipients. (In press). (Article Unavailable)*
- Ho M., et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children, Transplantation 45: 719-727, 1988.*
- Kenagy DN, et al., Epstein-Barr virus DNA in peripheral blood leukocytes with post-transplant lymphoproliferative disease. Transplant 60:547, 1995.*
- Kimura H., et al., Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J. Clin Microbiol. 37:132, 1999.*
- Landt, et al., Selection of Hybridization Probe Sequences for Use with the LightCycler, Roche Molecular*



LightCycler Principles, Biochem.Boehringer-Mannheim.

Loechelt, Brett J., et al., "*GM-CSF as Pre-Emptive Therapy for Post-Transplant EBV Disease*," 3 pgs, (2001).

Lucas KG, et al., *Semiquantitative Epstein-Barr virus DNA in blood of solid organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders*. J. Clin Microbiol. 38: 613, 2000. (Article Unavailable)

Martell, M., et al., *High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA*. J. Clin. Microbiol. 1999 Feb;37(2):327-32.

Martin, PJ, et al., *Fatal Epstein-Barr virus associated proliferation of donor B cells after treatment of acute graft vs-host disease with a murine anti-T-cell antibody*. Ann Intern Med 101:310, 1984.

Mercier B., et al., *Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using a novel TaqMan PCR assay*. J. Clin Microbiol. 1999 Jan;37(1):1-9.

Niesters H, et al., *Development of a real-time quantitative assay for detection of Epstein-Barr virus*. J. Clin Microbiol. 2000 Feb;38(2):712-5.

Papadopoulos EB, et al., *Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorder complicating allogeneic marrow transplantation*, N. Engl J. Med 330: 1185, 1994.

Rasmussen et al., *Quantitative PCR by Continuous Fluorescence Monitoring of a Double Strand DNA Specific Binding Dye*, Biochemica, No. 2, (1998).

Recombinant DNA Technology, *DNA Amplification by the Polymerase Chain Reaction*, Chapter 3, Nucleotides and Nucleic Acids.

Riddler SA, et al., *Increased levels of circulating Epstein-Barr virus (EBV) infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of post-transplant lymphoproliferative disease in solid-organ transplant recipients*. Blood 84:972, 1994.

Rogers B, et al., *Epstein-Barr virus polymerase chain reaction and serology in pediatric post-transplant lymphoproliferative disorder: three year experience*. Pediatric & Developmental Pathology 1: 480, 1998.

Savoie A, et al., *Direct correlation between the load of Epstein-Barr virus infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease*. Blood 83: 2715, 1994.

Shapiro, RS, et al., *Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation*. Blood 71: 1234, 1988.

Starzl T, et al., *Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin steroid therapy*, Lancet I: 583, 1984.

The LightCycler™ - the Smartest Innovation for More Efficient PCR, Biochemica, No. 2 (1998).

University of Chicago Cancer Research Center, DNA Sequencing Facility, *The Standard Primers*, April 17, 1997 update.

186 Zutter MM, et al. *Epstein-Barr virus lymphoproliferation after bone marrow transplantation*. Blood 72, 520, 1988.

EXAMINER Baigent

DATE CONSIDERED 08/20/2003

Page ____ of ____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CINlibrary/1218796.1



RECEIVED
NOV 27 2002
TECH CENTER 1600/2900